Julia TietzAssociate Director at Numab Therapeutics AG
Julia leads the Bioanalytics group at Numab Therapeutics, an emerging Swiss biotech company developing multiple immuno-oncology programs utilizing the versatile, multi-specific MATCH platform. In this position, she is responsible for the development of ELISA, cell-based and biomarker assays and leads a preclinical discovery project in the field of inflammation. Prior to joining Numab, Julia held a Team Leader position at ESBATech, a Novartis company, where she significantly contributed to the discovery and preclinical characterization of the VEGF inhibitor Beovu, a humanized single chain antibody recently approved by the FDA. Julia holds an MSc in Biology from the University of Neuchâtel, Switzerland.